Navigation Links
Proteomics Study Reveals That Genes Involved in Invertebrate Longevity Have Surprising Parallels in Humans.
Date:3/13/2009

SALT LAKE CITY, March 13 /PRNewswire/ -- Prolexys Pharmaceuticals announced today the publication of the discovery of genes that are likely to have a role in the aging process of humans. The findings result from research on the human equivalents of proteins from simple animals which confer long life in those species. The evidence suggests that these proteins are more likely to interact with other proteins in a large atlas of mapped interactions. Furthermore, the investigators were able to show that the protein associations also correlate with differences in gene expression between young and old humans. Though the existence of longevity-extending genes has been known for experimental organisms such as yeast, roundworms and flies, this is the first demonstration that similar genes have a role in the aging process of humans.

The proteins involved are defined as a network of 175 human equivalents of known invertebrate longevity genes and 2163 additional proteins in a complex network involving 3271 interactions. The research, published in the March 13, 2009 issue of PLoS Genetics, was a collaboration of scientists at Prolexys, The Buck Institute for Age Research in Novato, California, University of California in Berkeley and McMaster University in Hamilton, Ontario.

"This work continues to demonstrate that high-throughput screening for protein interactions combined with genetic and functional validation provides an opportunity to investigate complex biological processes such as aging. Furthermore, we would like to encourage scientists interested in aging and longevity to mine these data made available in the study," said Dr. Sudhir Sahasrabudhe, Chief Scientific Officer of Prolexys Pharmaceuticals.

"This establishes a similarity in aging process among diverse species that is perhaps a lot broader than many of us may have expected," says Robert Hughes, lead author of the study.

About Prolexys Pharmaceuticals, Inc.:

Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's current therapeutic focus is on cancer. Prolexys scientists have developed proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include:

a) A solid tumor oncology program in Phase 1 clinical trials with a small molecule, PRLX 93936, which targets advanced solid tumors that are otherwise refractory to the standard of care therapies.

b) A colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade.

Visit www.prolexys.com for more information.

About the Buck Institute:

The Buck Institute is the only freestanding institute in the United States that is devoted solely to basic research on aging and age-associated disease. The Institute is an independent nonprofit organization dedicated to extending the healthspan, the healthy years of each individual's life. The National Institute on Aging designated the Buck a "Nathan Shock Center of Excellence in the Biology of Aging," one of just five centers in the country. Buck Institute scientists work in an innovative, interdisciplinary setting to understand the mechanisms of aging and to discover new ways of detecting, preventing and treating conditions such as Alzheimer's and Parkinson's disease, cancer, diabetes and stroke. Collaborative research at the Institute is supported by new developments in genomics, proteomics and bioinformatics technology. For more information: www.buckinstitute.org.


'/>"/>
SOURCE Prolexys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Covance Purchases Equity Stake in Caprion Proteomics
2. Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics
3. Sigma-Aldrich Announces New Prestige Antibodies(TM) Line for Proteomics and Cell Biology Researchers
4. Bruker Announces Availability of New HUPO World Congress Proteomics Posters on Web Site
5. Angiotech announces positive results from Bio-Seal(TM) clinical study
6. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
7. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
8. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
9. QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
10. New Study Reports Improved Patient Outcomes for Breast Cancer Patients
11. Mouse study reveals genetic component of empathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):